Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab183320-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$189.90
|
|
|
Ab183320-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$919.90
|
|
|
Ab183320-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
|
Ab183320-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$3,679.90
|
|
Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| Product Name | Iladatuzumab vedotin (anti-CD79b) - Primary antibody, specific to CD79B, Purity>90% (SDS-PAGE&SEC), high purity, Human IgG1 |
|---|---|
| Synonyms | AGM6 antibody | B cell antigen receptor complex associated protein beta chain antibody | B cell specific glycoprotein B29 antibody | B-cell antigen receptor complex-associated protein beta chain antibody | B-cell-specific glycoprotein B29 antibody | B29 a |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances pho |
| Host species | Human |
| Specificity | CD79B |
| Conjugation | MC-VC-PAB-MMAE |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Iladatuzumab vedotin (anti-CD79b), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin (anti-CD79b) has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Purity | Purity>90% (SDS-PAGE&SEC) |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1906205-77-3 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Iladatuzumab vedotin (anti-CD79b) (Ab183320) - ELISA
Immobilized Recombinant Human CD79B protein (rp176729) at 1.0 μg/mL can bind Iladatuzumab vedotin (anti-CD79b) (Ab183320) with the EC50 of 47.25 ng/mL.
Iladatuzumab vedotin (anti-CD79b) (Ab183320) - SEC
The purity of Iladatuzumab vedotin (anti-CD79b) (Ab183320) is more than 95% verified by HPLC.